ODM meta - analysis

Deltex Medical Group PLC
03 March 2008


                            Deltex Medical Group plc


Independent analysis of clinical trial data further confirms clinical benefit of
        oesophageal Doppler-guided fluid delivery in abdominal surgery.


3 March 2008 - Deltex Medical Group plc ('Deltex Medical'), the UK's leading
haemodynamic monitoring company, notes the publication of an article in the
International Journal of Clinical Practice that examines the use of oesophageal
Doppler monitoring (ODM) to guide fluid delivery in patients undergoing major
abdominal surgery.

Doctors from the departments of surgery and anaesthesia at the Cambridge
University Hospitals NHS Trust examined results from the four previously
published randomised controlled clinical trials into the use of ODM in abdominal
surgery. The results, involving a total of almost 400 patients, were combined
using the stringent statistical technique known as meta-analysis.

The authors reported that use of ODM in abdominal surgery, based on the pooled
data analysed, resulted in significantly fewer post-operative complications and
a consequent significant reduction in length of hospital stay.

Deltex Medical's Chief Executive, Andy Hill commented:

'This article further supports the growing belief that the use of Deltex
Medical's CardioQ(TM) oesophageal Doppler monitor to guide fluid delivery should 
be routine clinical practice in abdominal and other major surgery.'

The full reference for the article is:

Walsh SR, Tang T, Bass S and Gaunt ME. Doppler-guided intra-operative fluid
management during major abdominal surgery: systematic review and meta-analysis
Int J Clin Pract. March 2008. 62, 3 466-470


For further information, please contact:-

Deltex Medical Group plc                        01243 774 837

Nigel Keen, Chairman                            [e-mail]
Andy Hill, Chief Executive                      [e-mail]
Ewan Phillips, Finance Director                 [e-mail]

Gavin Anderson & Company                        020 7554 1400

Deborah Walter                                  [e-mail]
Robert Speed                                    [e-mail]

Charles Stanley Securities                      020 7149 6000

Nominated Advisor
Philip Davies                                   [e-mail]
Russell Cook                                    [e-mail]


Notes for Editors

Deltex Medical manufactures and markets the CardioQ(TM) monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs. This causes medical
complications including peripheral and major organ failure which can lead to
death. Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself. Using fluids and drugs, guided by the CardioQ, to optimise the amount of
circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-

   •    Validated the results of the Monitor against known standards for
        measuring cardiac output, demonstrating that the technology works

   •    Proved that the CardioQ works in a wide range of surgical procedures

   •    Demonstrated that the Company's technology provides significant health
        and economic benefits by helping to reduce post-operative complications 
        and length of hospital stays by an average of 30 to 40 per cent for a 
        wide range of patients.

The SupraQ(TM) is an entirely non-invasive device which uses an ultrasound probe
held at the base of the patient's neck to track the flow of blood in the aorta;
it presents the same data as the CardioQ in a similar format and is used for
taking snapshots or monitoring over short periods.



                      This information is provided by RNS
            The company news service from the London Stock Exchange